Identification

Name
Rescinnamine
Accession Number
DB01180  (APRD00112)
Type
Small Molecule
Groups
Approved
Description

Rescinnamine is an angiotensin-converting enzyme inhibitor used as an antihypertensive drug. It is an alkaloid obtained from Rauwolfia serpentina and other species of Rauwolfia. [Wikipedia]

Structure
Thumb
Synonyms
  • 3,4,5-Trimethoxycinnamoyl methyl reserpate
  • Rescinnamine
  • Trimethoxy cinnamoyl reserpate de methyl
  • Tsuruselpi S
International/Other Brands
Tsuruselpi S
Categories
UNII
Q6W1F7DJ2D
CAS number
24815-24-5
Weight
Average: 634.716
Monoisotopic: 634.289030952
Chemical Formula
C35H42N2O9
InChI Key
SZLZWPPUNLXJEA-QEGASFHISA-N
InChI
InChI=1S/C35H42N2O9/c1-40-21-8-9-22-23-11-12-37-18-20-15-29(46-30(38)10-7-19-13-27(41-2)33(43-4)28(14-19)42-3)34(44-5)31(35(39)45-6)24(20)17-26(37)32(23)36-25(22)16-21/h7-10,13-14,16,20,24,26,29,31,34,36H,11-12,15,17-18H2,1-6H3/b10-7+/t20-,24+,26-,29-,31+,34+/m1/s1
IUPAC Name
methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-{[3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]oxy}-3,13-diazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4(9),5,7-tetraene-19-carboxylate
SMILES
[H][[email protected]]12C[[email protected]@H](OC(=O)C=CC3=CC(OC)=C(OC)C(OC)=C3)[[email protected]](OC)[[email protected]@H](C(=O)OC)[[email protected]@]1([H])C[[email protected]@]1([H])N(CCC3=C1NC1=C3C=CC(OC)=C1)C2

Pharmacology

Indication

For the treatment of hypertension.

Structured Indications
Not Available
Pharmacodynamics

Used to treat hypertension. Rescinnamine inhibits angiotensin-converting enzyme. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex and general vasoconstriction, both of which lead to increases vascular resistance. By inhibiting angiotensin II, aldosterone reabsorption is decreased as well as vasoconstriction. This combined effect serves to decrease blood pressure.

Mechanism of action

Rescinnamine Binds to and inhibits the angiotensin converting enzyme. Rescinnamine competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion.

TargetActionsOrganism
AAngiotensin-converting enzyme
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Rescinnamine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Limonene, (+)-.Investigational
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Rescinnamine.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Rescinnamine.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Rescinnamine can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Rescinnamine.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Adapalene.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Alclofenac.Approved, Withdrawn
AlfuzosinAlfuzosin may increase the hypotensive activities of Rescinnamine.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Rescinnamine.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Rescinnamine.Approved
AlminoprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Alminoprofen.Experimental
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Rescinnamine.Approved
AloxiprinAloxiprin may decrease the antihypertensive activities of Rescinnamine.Experimental
AlprenololAlprenolol may increase the hypotensive activities of Rescinnamine.Approved, Withdrawn
AmbrisentanRescinnamine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineRescinnamine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideAmiloride may increase the hyperkalemic activities of Rescinnamine.Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Rescinnamine.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Rescinnamine.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Rescinnamine.Approved, Illicit
AndrographolideThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Andrographolide.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Antipyrine.Approved
ApocyninThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Apocynin.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Apremilast.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Rescinnamine.Approved, Withdrawn
ArdeparinArdeparin may increase the hyperkalemic activities of Rescinnamine.Approved, Investigational, Withdrawn
AtenololAtenolol may increase the hypotensive activities of Rescinnamine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Rescinnamine.Approved
AvanafilAvanafil may increase the antihypertensive activities of Rescinnamine.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Azapropazone.Withdrawn
AzathioprineRescinnamine may increase the myelosuppressive activities of Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Rescinnamine.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Balsalazide.Approved, Investigational
BarnidipineRescinnamine may increase the antihypertensive activities of Barnidipine.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Rescinnamine.Approved, Investigational
BenazeprilBenazepril may increase the hypotensive activities of Rescinnamine.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Bendazac.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Rescinnamine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Rescinnamine.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Benzydamine.Approved
BepridilBepridil may increase the hypotensive activities of Rescinnamine.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Rescinnamine.Approved
BethanidineBethanidine may increase the hypotensive activities of Rescinnamine.Approved
BevoniumThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Bevonium.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Rescinnamine.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Rescinnamine.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Rescinnamine.Approved
BosentanBosentan may increase the hypotensive activities of Rescinnamine.Approved, Investigational
BQ-123BQ-123 may increase the hypotensive activities of Rescinnamine.Investigational
BretyliumBretylium may increase the hypotensive activities of Rescinnamine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Rescinnamine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Rescinnamine.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Bucillamine.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Bufexamac.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Bumadizone.Experimental
BumetanideBumetanide may increase the hypotensive activities of Rescinnamine.Approved
BupranololBupranolol may increase the hypotensive activities of Rescinnamine.Approved
CadralazineCadralazine may increase the hypotensive activities of Rescinnamine.Experimental
CafedrineCafedrine may increase the hypotensive activities of Rescinnamine.Investigational
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Rescinnamine.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Rescinnamine.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Rescinnamine.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Rescinnamine.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Rescinnamine.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Rescinnamine.Experimental, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Rescinnamine.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Rescinnamine.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Rescinnamine.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Rescinnamine.Approved, Investigational
CertoparinCertoparin may increase the hyperkalemic activities of Rescinnamine.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Rescinnamine.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Rescinnamine.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Choline magnesium trisalicylate.Approved
CicletanineCicletanine may increase the hypotensive activities of Rescinnamine.Investigational
CilazaprilCilazapril may increase the hypotensive activities of Rescinnamine.Approved
CiprofloxacinRescinnamine may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
ClonidineClonidine may increase the hypotensive activities of Rescinnamine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Clonixin.Approved
CloranololCloranolol may increase the hypotensive activities of Rescinnamine.Experimental
CryptenamineCryptenamine may increase the hypotensive activities of Rescinnamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Curcumin.Investigational
CyclopenthiazideCyclopenthiazide may increase the hypotensive activities of Rescinnamine.Experimental
CyclothiazideCyclothiazide may increase the hypotensive activities of Rescinnamine.Approved
DalteparinDalteparin may increase the hyperkalemic activities of Rescinnamine.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Rescinnamine.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Rescinnamine.Approved, Investigational
DelaprilDelapril may increase the hypotensive activities of Rescinnamine.Experimental
DersalazineDersalazine may decrease the antihypertensive activities of Rescinnamine.Investigational
DeserpidineDeserpidine may increase the hypotensive activities of Rescinnamine.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Rescinnamine.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Diclofenac.Approved, Vet Approved
DiethylnorspermineDiethylnorspermine may increase the hypotensive activities of Rescinnamine.Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Difenpiramide.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Rescinnamine.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Rescinnamine.Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Rescinnamine.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Rescinnamine.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Rescinnamine.Approved
DrospirenoneRescinnamine may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Rescinnamine is combined with E-6201.Investigational
EfonidipineEfonidipine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
EnalaprilEnalapril may increase the hypotensive activities of Rescinnamine.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the hypotensive activities of Rescinnamine.Approved
EndralazineEndralazine may increase the hypotensive activities of Rescinnamine.Experimental
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Rescinnamine.Approved
EpanololEpanolol may increase the hypotensive activities of Rescinnamine.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Rescinnamine.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Rescinnamine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Rescinnamine.Approved
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Rescinnamine.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Ethenzamide.Experimental
EtodolacThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Evening primrose oil.Approved, Investigational
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Rescinnamine.Approved
ExisulindThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Felbinac.Experimental
FelodipineFelodipine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Rescinnamine.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Fenoprofen.Approved
FentiazacThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Feprazone.Experimental
Ferulic acidFerulic acid may increase the hypotensive activities of Rescinnamine.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Rescinnamine.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Flunoxaprofen.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Flurbiprofen.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Rescinnamine.Experimental
FosinoprilFosinopril may increase the hypotensive activities of Rescinnamine.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Rescinnamine.Approved, Investigational, Vet Approved
FurosemideFurosemide may increase the hypotensive activities of Rescinnamine.Approved, Vet Approved
GuacetisalGuacetisal may decrease the antihypertensive activities of Rescinnamine.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Rescinnamine.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Rescinnamine.Approved
GuanazodineRescinnamine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Rescinnamine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
GuanoclorRescinnamine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzRescinnamine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanRescinnamine may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Rescinnamine.Experimental
Hemoglobin crosfumarilHemoglobin crosfumaril may decrease the antihypertensive activities of Rescinnamine.Experimental
HeparinHeparin may increase the hyperkalemic activities of Rescinnamine.Approved, Investigational
HexamethoniumHexamethonium may increase the hypotensive activities of Rescinnamine.Experimental
HigenamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Rescinnamine.Experimental
HydralazineHydralazine may increase the hypotensive activities of Rescinnamine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Rescinnamine.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Rescinnamine.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Ibuproxam.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Rescinnamine.Approved
IloprostIloprost may increase the hypotensive activities of Rescinnamine.Approved, Investigational
ImidaprilImidapril may increase the hypotensive activities of Rescinnamine.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Imidazole salicylate.Experimental
IndapamideIndapamide may increase the hypotensive activities of Rescinnamine.Approved
IndenololIndenolol may increase the hypotensive activities of Rescinnamine.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Rescinnamine.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Rescinnamine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Rescinnamine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Rescinnamine.Approved, Investigational
IronThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Iron.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Rescinnamine.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Isoxicam.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Rescinnamine.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Rescinnamine.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Ketorolac.Approved
LabetalolLabetalol may increase the hypotensive activities of Rescinnamine.Approved
LacidipineLacidipine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
Lanthanum carbonateThe serum concentration of Rescinnamine can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Rescinnamine.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Rescinnamine.Approved
LinsidomineLinsidomine may increase the hypotensive activities of Rescinnamine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Rescinnamine.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Rescinnamine.Approved
LofexidineLofexidine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Rescinnamine.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Loxoprofen.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Lumiracoxib.Approved, Investigational
MacitentanRescinnamine may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Magnesium salicylate.Approved
ManidipineManidipine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Masoprocol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Rescinnamine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Rescinnamine.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Meloxicam.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Rescinnamine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Metamizole.Investigational, Withdrawn
MethoserpidineRescinnamine may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideMethyclothiazide may increase the hypotensive activities of Rescinnamine.Approved
Methyl salicylateMethyl salicylate may decrease the antihypertensive activities of Rescinnamine.Approved, Vet Approved
MethyldopaMethyldopa may increase the hypotensive activities of Rescinnamine.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Rescinnamine.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Rescinnamine.Approved, Investigational
MetipranololMetipranolol may increase the hypotensive activities of Rescinnamine.Approved
MetolazoneMetolazone may increase the hypotensive activities of Rescinnamine.Approved
MetoprololMetoprolol may increase the hypotensive activities of Rescinnamine.Approved, Investigational
MetyrosineMetyrosine may increase the hypotensive activities of Rescinnamine.Approved
MibefradilMibefradil may increase the hypotensive activities of Rescinnamine.Investigational, Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Rescinnamine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Rescinnamine.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Rescinnamine.Investigational
MizoribineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Rescinnamine.Approved
MoexiprilMoexipril may increase the hypotensive activities of Rescinnamine.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
MuzolimineMuzolimine may increase the hypotensive activities of Rescinnamine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Nabumetone.Approved
NadololNadolol may increase the hypotensive activities of Rescinnamine.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Rescinnamine.Approved
NafamostatThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Naftifine.Approved
NaftopidilNaftopidil may increase the hypotensive activities of Rescinnamine.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Naproxen.Approved, Vet Approved
NebivololNebivolol may increase the hypotensive activities of Rescinnamine.Approved, Investigational
NepafenacThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Nepafenac.Approved
NialamideNialamide may increase the hypotensive activities of Rescinnamine.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Rescinnamine.Approved
NicorandilNicorandil may increase the hyperkalemic activities of Rescinnamine.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Niflumic Acid.Approved
NiguldipineNiguldipine may increase the hypotensive activities of Rescinnamine.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Rescinnamine.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Rescinnamine.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Rescinnamine.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Rescinnamine.Approved
ObinutuzumabRescinnamine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Rescinnamine.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Rescinnamine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Olsalazine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Rescinnamine.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Oxaprozin.Approved
OxprenololOxprenolol may increase the hypotensive activities of Rescinnamine.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Oxyphenbutazone.Approved, Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Rescinnamine.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Rescinnamine.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Parthenolide.Investigational
PenbutololPenbutolol may increase the hypotensive activities of Rescinnamine.Approved, Investigational
PentoliniumPentolinium may increase the hypotensive activities of Rescinnamine.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Rescinnamine.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Rescinnamine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Rescinnamine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Rescinnamine.Withdrawn
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Rescinnamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Rescinnamine.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Rescinnamine.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Pimecrolimus.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Rescinnamine.Withdrawn
PindololPindolol may increase the hypotensive activities of Rescinnamine.Approved
PiretanidePiretanide may increase the hypotensive activities of Rescinnamine.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Pirfenidone.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Rescinnamine.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Rescinnamine.Withdrawn
Platelet Activating FactorPlatelet Activating Factor may increase the hypotensive activities of Rescinnamine.Experimental
PolythiazidePolythiazide may increase the hypotensive activities of Rescinnamine.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Pranoprofen.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Rescinnamine.Approved
PregabalinThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Pregabalin.Approved, Illicit, Investigational
ProcarbazineProcarbazine may increase the hypotensive activities of Rescinnamine.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Propacetamol.Approved, Investigational
PropranololPropranolol may increase the hypotensive activities of Rescinnamine.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Proquazone.Experimental
PTC299The risk or severity of adverse effects can be increased when Rescinnamine is combined with PTC299.Investigational
QuinaprilQuinapril may increase the hypotensive activities of Rescinnamine.Approved, Investigational
QuinethazoneQuinethazone may increase the hypotensive activities of Rescinnamine.Approved
RamiprilRamipril may increase the hypotensive activities of Rescinnamine.Approved
RasagilineRasagiline may increase the hypotensive activities of Rescinnamine.Approved
RemikirenRemikiren may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Rescinnamine.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Rescinnamine.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Rescinnamine.Investigational
RiociguatRescinnamine may increase the hypotensive activities of Riociguat.Approved
RituximabRescinnamine may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Rofecoxib.Investigational, Withdrawn
SacubitrilThe risk or severity of angioedema can be increased when Rescinnamine is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Rescinnamine.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Salicylamide.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Rescinnamine.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Rescinnamine.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Rescinnamine.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Rescinnamine.Approved
SelegilineSelegiline may increase the hypotensive activities of Rescinnamine.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the hypotensive activities of Rescinnamine.Approved
SemapimodThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Serrapeptase.Investigational
SildenafilSildenafil may increase the antihypertensive activities of Rescinnamine.Approved, Investigational
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Rescinnamine.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Rescinnamine.Approved, Investigational
SitaxentanRescinnamine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Sodium aurothiomalate.Approved
Sodium phosphateRescinnamine may increase the nephrotoxic activities of Sodium phosphate.Approved
SpiraprilSpirapril may increase the hypotensive activities of Rescinnamine.Approved
SpironolactoneSpironolactone may increase the hyperkalemic activities of Rescinnamine.Approved
SRT501The risk or severity of adverse effects can be increased when Rescinnamine is combined with SRT501.Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Suxibuzone.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Rescinnamine.Approved, Investigational
TalinololTalinolol may increase the hypotensive activities of Rescinnamine.Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Rescinnamine.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Rescinnamine.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of Rescinnamine.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Rescinnamine.Approved
TenidapThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tenidap.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Teriflunomide.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Rescinnamine.Approved, Investigational
TetrahydropalmatineTetrahydropalmatine may increase the hypotensive activities of Rescinnamine.Investigational
TheodrenalineTheodrenaline may increase the hypotensive activities of Rescinnamine.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tiaprofenic acid.Approved
TiboloneTibolone may increase the hypotensive activities of Rescinnamine.Approved, Investigational
TicrynafenTicrynafen may increase the hypotensive activities of Rescinnamine.Withdrawn
TimololTimolol may increase the hypotensive activities of Rescinnamine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Rescinnamine.Approved
TizanidineTizanidine may increase the hypotensive activities of Rescinnamine.Approved
TolazolineTolazoline may increase the hypotensive activities of Rescinnamine.Approved, Vet Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tolmetin.Approved
TolonidineRescinnamine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Rescinnamine.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Rescinnamine.Approved
TorasemideTorasemide may increase the hypotensive activities of Rescinnamine.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Rescinnamine.Approved
TranilastThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Rescinnamine.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Rescinnamine.Approved
TravoprostTravoprost may increase the hypotensive activities of Rescinnamine.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Rescinnamine.Approved, Investigational
TriamtereneTriamterene may increase the hyperkalemic activities of Rescinnamine.Approved
TribenosideThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tribenoside.Experimental
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Rescinnamine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Rescinnamine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Rescinnamine.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Rescinnamine.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Triptolide.Investigational
Trolamine salicylateTrolamine salicylate may decrease the antihypertensive activities of Rescinnamine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Rescinnamine.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Rescinnamine.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Rescinnamine.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Valdecoxib.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Rescinnamine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Rescinnamine.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Rescinnamine.Approved, Investigational
VincamineVincamine may increase the hypotensive activities of Rescinnamine.Experimental
VinpocetineVinpocetine may increase the hypotensive activities of Rescinnamine.Investigational
XipamideXipamide may increase the hypotensive activities of Rescinnamine.Experimental
XylometazolineXylometazoline may increase the hypotensive activities of Rescinnamine.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Rescinnamine.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilZofenopril may increase the hypotensive activities of Rescinnamine.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Zomepirac.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Drug
D00198
KEGG Compound
C06540
PubChem Compound
32681
PubChem Substance
46507786
ChemSpider
4444446
ChEBI
28572
ChEMBL
CHEMBL1668
Therapeutic Targets Database
DAP000910
PharmGKB
PA164768818
Wikipedia
Rescinnamine
ATC Codes
C02AA01 — RescinnamineC02LA02 — Rescinnamine and diureticsC02LA52 — Rescinnamine and diuretics, combinations with other drugs
MSDS
Download (52.7 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)238.5 °CPhysProp
logP3.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00349 mg/mLALOGPS
logP4.48ALOGPS
logP4.07ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)16.29ChemAxon
pKa (Strongest Basic)7.56ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area117.78 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity171.16 m3·mol-1ChemAxon
Polarizability69.65 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9604
Blood Brain Barrier+0.9248
Caco-2 permeable+0.6805
P-glycoprotein substrateSubstrate0.8163
P-glycoprotein inhibitor IInhibitor0.8826
P-glycoprotein inhibitor IINon-inhibitor0.6553
Renal organic cation transporterInhibitor0.5
CYP450 2C9 substrateNon-substrate0.8706
CYP450 2D6 substrateNon-substrate0.9064
CYP450 3A4 substrateSubstrate0.7223
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9144
CYP450 3A4 inhibitorNon-inhibitor0.8203
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7162
Ames testNon AMES toxic0.9208
CarcinogenicityNon-carcinogens0.9453
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8345 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.697
hERG inhibition (predictor II)Non-inhibitor0.678
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (13.2 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as yohimbine alkaloids. These are alkaloids containing the pentacyclic yohimban skeleton. The Yohimbinoid alkaloids contain a carbocyclic ring E arising through C-17 to C-18 bond formation in a corynantheine precursor.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Yohimbine alkaloids
Sub Class
Not Available
Direct Parent
Yohimbine alkaloids
Alternative Parents
Corynanthean-type alkaloids / Beta carbolines / Cinnamic acid esters / Coumaric acids and derivatives / 3-alkylindoles / Styrenes / Phenoxy compounds / Anisoles / Methoxybenzenes / Alkyl aryl ethers
show 16 more
Substituents
Yohimbine / Corynanthean skeleton / Yohimbine alkaloid / Pyridoindole / Beta-carboline / Cinnamic acid or derivatives / Coumaric acid or derivatives / Cinnamic acid ester / 3-alkylindole / Indole or derivatives
show 38 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
Gene Name
ACE
Uniprot ID
P12821
Uniprot Name
Angiotensin-converting enzyme
Molecular Weight
149713.675 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Azhar I, Mazhar F, Manzar QN, Hussain I, Shamim S: Colorimetric determination of indolic drugs. Pak J Pharm Sci. 2005 Apr;18(2):48-51. [PubMed:16431399]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on June 13, 2005 07:24 / Updated on December 01, 2017 14:40